FDA+ roundup: Assessor finds FDA's new biosimilar review model makes the process more predictable
As Congress preps to re-authorize the next round of biosimilar user fees before the end of September, an independent assessor’s final report from BsUFA II …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
